Laufer; Ralph

Patent Applications and Registrations

Patent applications and USPTO patent grants for Laufer; Ralph.The latest application filed is for "treatment of neurodegenerative eye disease using pridopidine".

Company Profile

4.8.17

Laufer; Ralph - Tel Aviv IL
LAUFER; Ralph - Neuilly sur Seine FR
Laufer; Ralph - Pomezia IT
LAUFER; Ralph - Pomezia RM
Laufer; Ralph - Rome IT

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Method of treating amyotrophic lateral sclerosis with pridopidine Grant 11,406,625 - Geva , et al. August 9, 2	2022-08-09
Treatment Of Neurodegenerative Eye Disease Using Pridopidine App 20220062255 - Geva; Michal ; et al.	2022-03-03
Compositions And Methods For Treating Gm1 Gangliosidosis And Other Disorders App 20210355506 - HOCQUEMILLER; Michael ; et al.	2021-11-18
Use Of Pridopidine For The Treatment Of Anxiety And Depression App 20210106572 - GEVA; Michal ; et al.	2021-04-15
Method Of Treating Amyotrophic Lateral Sclerosis With Pridopidine App 20200179355 - GEVA; Michal ; et al.	2020-06-11
Prodrugs of Chlorokynurenines App 20190308934 - Laufer; Ralph ; et al.	2019-10-10
Treatment Of Neurodegenerative Eye Disease Using Prodopidine App 20190046516 - Russ; Hermann Kurt ; et al.	2019-02-14
Prodrugs Of Chlorokynurenines App 20180327351 - LAUFER; Ralph ; et al.	2018-11-15
Deuterated Chlorokynurenines For The Treatment Of Neuropsychiatric Disorders App 20180305298 - OTT; Gregory R. ; et al.	2018-10-25
Substituted Cyclohexanones App 20180289637 - Laufer; Ralph ; et al.	2018-10-11
Tetrahydrocarbazole Inhibitors Of SIRT1 Receptors App 20180127366 - Zhang; Chengzhi ; et al.	2018-05-10
Tetrahydrocarbazole inhibitors of SIRT1 receptors Grant 9,884,819 - Zhang , et al. February 6, 2	2018-02-06
Tetrahydrocarbazole Inhibitors Of SIRT1 Receptors App 20170190664 - Zhang; Chengzhi ; et al.	2017-07-06
Compounds for use in the treatment of disorders that are ameliorated by inhibition of HDAC Grant 9,371,295 - Altamura , et al. June 21, 2	2016-06-21
Compounds for use in the treatment of parasitic diseases Grant 9,365,541 - Altamura , et al. June 14, 2	2016-06-14
Compounds For Use In The Treatment Of Parasitic Diseases App 20150299163 - ALTAMURA; Sergio ; et al.	2015-10-22
Compounds For Use In The Treatment Of Disorders That Are Ameliorated By Inhibition Of Hdac App 20150218112 - Altamura; Sergio ; et al.	2015-08-06
Assay for cytochrome P450 isoform 2C9 Grant 7,629,140 - Laufer , et al. December 8, 2	2009-12-08
Assay for Cytochrome P450 Isoform 2C9 App 20080193950 - Laufer; Ralph ; et al.	2008-08-14
Assay for Cytochrome P450 Isoforms 3A4 and 3A5 App 20080145886 - Laufer; Ralph ; et al.	2008-06-19
Cytochrome P450 Induction Assay App 20070264674 - Paonessa; Giacomo ; et al.	2007-11-15
Method of screening for anti-obesity agents using ciliary neutrophic factor receptor Grant 6,960,558 - Ciliberto , et al. November 1, 2	2005-11-01
Variants of human ciliary neurotrophic factor (hCNTF) Grant 6,756,357 - Laufer , et al. June 29, 2	2004-06-29
Variant of ciliary neurotrophic factor and DNA encoding the variant Grant 6,660,467 - Gloaguen , et al. December 9, 2	2003-12-09
Use of CNTF (ciliary neurotrophic factor) receptor activators for the treatment of obesity App 20030176346 - Ciliberto, Gennaro ; et al.	2003-09-18

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.